Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis

Christine Hale,Frances Bowe,Derek Pickard,Simon Clare,Jean-Francois Haeuw,Ultan Powers,Nathalie Menager,Pietro Mastroeni,Gordon Dougan
DOI: https://doi.org/10.1016/j.vaccine.2006.03.002
IF: 4.169
2006-05-15
Vaccine
Abstract:Immunisation of BALB/c mice with a vaccine containing Vi polysaccharide conjugated to the Klebsiella pneumoniae outer membrane 40 kDa protein (rP40), in combination with Escherichia coli heat-labile toxin adjuvant (LT), elicited anti-Vi IgG antibodies after administration using different routes. Testing of the immune serum in opsonisation assays demonstrated the specific enhancement of Vi-positive bacterial uptake by cultured murine bone marrow derived macrophages. Intra-peritoneal challenge of mice immunised with the Vi-based vaccine elicited a degree of protection against virulent Vi+ Salmonella enterica serovar typhimurium (S. typhimurium). In contrast, Vi vaccination did not confer protection against oral challenge with virulent Vi-positive S. typhimurium or S. dublin.
What problem does this paper attempt to address?